IMRX Stock Analysis: Buy, Sell, or Hold?
IMRX - Immuneering Corporation Class A Common Stock
$5.19
0.03 (0.58%)
▲
5d:
+1.76%
30d:
+25.97%
90d:
-8.95%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 12, 2026
28d
Get Alerted When IMRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called IMRX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IMRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IMRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IMRX is currently trading at $5.19, which is considered extended relative to its 30-day fair value range of $4.15 to $5.05.
Technical Outlook: Technically, IMRX is in a strong uptrend. Immediate support is located at $4.64, while resistance sits at $5.70.
Market Sentiment: IMRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.86 (+246.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IMRX is in a strong uptrend. Immediate support is located at $4.64, while resistance sits at $5.70.
Market Sentiment: IMRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.86 (+246.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.15 -
$5.05
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 246.1% below Wall St target ($17.86)
Trading Range Analysis
30-Day Trading Range
$4.15 -
$5.05
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.64
Resistance Level
$5.70
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.87
Wall Street Target
$17.86
(+246.1%)
Revenue Growth (YoY)
-99.8%
Share & Embed Analysis
Last updated: July 14, 2026 11:17 AM ET
Data refreshes hourly during market hours. Next update: 12:17 PM
Data refreshes hourly during market hours. Next update: 12:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMRX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Harold Eugene Brakewood
BUY
5250 shares
2026-01-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
